Drug intelligence / Profile preview

LZ-Flu-001

Development stage: Preclinical
Lead developer: Beijing Luzhu Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LZ-Flu-001 is a preclinical-stage recombinant protein vaccine candidate developed by Beijing Luzhu Biotechnology (Green Bamboo Biopharmaceutical) for the prevention of influenza. The vaccine is designed to elicit protective immune responses by presenting specific influenza viral antigens to the host's immune system. As a recombinant protein-based product, it aims to provide a safer and more efficient manufacturing alternative to traditional egg-derived influenza vaccines, potentially reducing production lead times and avoiding egg-adaptive mutations that can affect vaccine efficacy.

Beyond the preview

Go deeper on LZ-Flu-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZ-Flu-001.

Explore the full profile